Probabilities of molecular remission at 2 years post-initial DLI for 66 patients treated for relapse after allogeneic SCT for CML
| Variable . | No. of patients . | 2-yr probability of molecular remission % (95% CI) . | P value . |
|---|---|---|---|
| Type of relapse at time of DLI | |||
| Molecular | 8 | 100 | |
| Cytogenetic | 19 | 84 (62-94) | .0003 |
| Hematologic, CP | 30 | 55 (38-78) | |
| Hematologic, AP | 9 | 29 (8-64) | |
| Interval SCT to relapse | |||
| <9 months | 25 | 56 (33-76) | .08 |
| ≥9 months | 41 | 76 (61-89) | |
| Interval relapse to DLI | |||
| <9 months | 28 | 73 (53-87) | .31 |
| ≥9 months | 38 | 66 (49-79) | |
| GVHD prophylaxis | |||
| Non-TCD | 22 | 55 (34-74) | .19 |
| TCD | 44 | 76 (58-83) | |
| Patient sex | |||
| Male | 31 | 72 (52-86) | .87 |
| Female | 35 | 66 (47-80) | |
| Donor sex | |||
| Male | 46 | 72 (57-84) | .19 |
| Female | 19 | 58 (32-80) | |
| Donor match | |||
| Identical sibling | 35 | 65 (47-80) | .20 |
| Matched unrelated | 31 | 75 (55-88) | |
| AGVHD grade post SCT | |||
| 0-1 | 41 | 67 (50-80) | .53 |
| 2-4 | 25 | 63 (43-80) | |
| CGVHD post-SCT | |||
| Nil | 33 | 70 (51-84) | .66 |
| Limited/extensive | 31 | 67 (48-82) |
| Variable . | No. of patients . | 2-yr probability of molecular remission % (95% CI) . | P value . |
|---|---|---|---|
| Type of relapse at time of DLI | |||
| Molecular | 8 | 100 | |
| Cytogenetic | 19 | 84 (62-94) | .0003 |
| Hematologic, CP | 30 | 55 (38-78) | |
| Hematologic, AP | 9 | 29 (8-64) | |
| Interval SCT to relapse | |||
| <9 months | 25 | 56 (33-76) | .08 |
| ≥9 months | 41 | 76 (61-89) | |
| Interval relapse to DLI | |||
| <9 months | 28 | 73 (53-87) | .31 |
| ≥9 months | 38 | 66 (49-79) | |
| GVHD prophylaxis | |||
| Non-TCD | 22 | 55 (34-74) | .19 |
| TCD | 44 | 76 (58-83) | |
| Patient sex | |||
| Male | 31 | 72 (52-86) | .87 |
| Female | 35 | 66 (47-80) | |
| Donor sex | |||
| Male | 46 | 72 (57-84) | .19 |
| Female | 19 | 58 (32-80) | |
| Donor match | |||
| Identical sibling | 35 | 65 (47-80) | .20 |
| Matched unrelated | 31 | 75 (55-88) | |
| AGVHD grade post SCT | |||
| 0-1 | 41 | 67 (50-80) | .53 |
| 2-4 | 25 | 63 (43-80) | |
| CGVHD post-SCT | |||
| Nil | 33 | 70 (51-84) | .66 |
| Limited/extensive | 31 | 67 (48-82) |
DLI, donor lymphocyte infusion; SCT, stem cell transplantation; CML, chronic myeloid leukemia; CI, confidence interval; CP, chronic phase; AP, advanced phase; GVHD, graft-versus-host disease; TCD, in vitro or in vivo T-cell depletion with Campath (CD52) monoclonal antibodies; AGVHD, acute graft-versus-host disease; CGVHD, chronic graft-versus-host disease.